The Pneumetron
NEWSTOOLSINFRASTRUCTURE
Pneumetron.Isomorphic Labs Secures $5B Series C to Advance AI Drug Design Platform
Share
Skip to article content
  1. Home
  2. ›
  3. News
  4. ›
  5. Technology
  6. ›
  7. Isomorphic Labs Secures $5B Series C to Advance AI Drug Design Platform
Technology·November 18, 2026

Isomorphic Labs Secures $5B Series C to Advance AI Drug Design Platform

BY PNEUMETRON|5 MIN READ · 991 WORDS5 MIN READ|
Tools
Share

In This Article

  • Capital Deployment and Investor Composition
  • The IsoDDE Platform and Technical Architecture
  • Clinical Pipeline and Pharmaceutical Partnerships
  • DeepMind Restructuring and Research Realignment
  • Funding Round Comparison
  • Technical Limitations and Validation Gaps
  • Sources
Illustrative photo: dna, biology, science, dna helix
Illustrative image: PublicDomainPictures / Pixabay

Isomorphic Labs raises $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital to advance its IsoDDE platform toward clinical trials. The funding follows a $2.1 billion Series B in May and signals sustained institutional capital for simulation-driven drug discovery.

Key Takeaways

  • 01Isomorphic Labs raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital.
  • 02The funding follows a $2.1 billion Series B completed in May 2026.
  • 03The company will advance its IsoDDE platform and push candidates into clinical trials.
  • 04DeepMind disbanded its original AlphaFold team in July 2026 amid the restructuring.

Isomorphic Labs has secured $5 billion in a Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and all existing backers. The announcement, published on November 17, 2026, marks the second multi-billion-dollar capital injection for the Alphabet-backed AI drug-discovery platform in less than six months.

This capital deployment signals a decisive industry pivot from foundational computational biology toward clinical-stage development. By allocating funds to advance its proprietary IsoDDE platform and expand therapeutic indications, Isomorphic is attempting to translate decades of academic protein-folding research into commercially viable pharmaceutical pipelines. The round also reflects sustained institutional confidence in simulation-based chemistry, despite the sector’s historical attrition rates and the absence of any FDA-approved drugs from the company to date.

Capital Deployment and Investor Composition

The $5 billion Series C follows a $2.1 billion Series B round completed in May 2026. Greenoaks and Sequoia Capital co-led the latest tranche, while Andreessen Horowitz joined as a new institutional backer. All prior investors maintained their participation, including Alphabet’s venture arms GV and Capita G, alongside Thrive Capital, MGX, Temasek, and the U.K. Sovereign AI Fund. Isomorphic declined to disclose its post-money valuation, though Bloomberg reported in early November that the company targeted a $50 billion valuation during negotiations.

Management indicated the capital will primarily finance the continued development of its drug-design engine and facilitate expansion into additional therapeutic categories. The funding cycle coincides with a leadership transition at the company’s helm. Founder and CEO Demis Hassabis stepped down from day-to-day operations at Google DeepMind in August 2026 to concentrate exclusively on pharmaceutical development, assuming a chairman role at DeepMind and taking on the title of Alphabet’s Chief Scientist.

Illustrative photo: laboratory, test tubes, healthcare worker, hospital Illustrative image: DarkoStojanovic / Pixabay

The IsoDDE Platform and Technical Architecture

Founded in 2021 as a spinout from Google’s DeepMind, Isomorphic operates an AI drug-design engine powered by simulation AI models that systematically explore various areas of chemistry. The company’s computational framework explicitly builds upon the AlphaFold protein-folding architecture, which demonstrated the ability to predict three-dimensional protein structures directly from genetic sequences without requiring experimental crystallography data.

The current iteration of the company’s proprietary system, designated IsoDDE (Isomorphic Drug Design Engine), extends beyond the capabilities of AlphaFold 3. According to the company, IsoDDE is engineered to improve the accuracy of drug binding and docking site predictions, a critical bottleneck in traditional molecular design. The platform integrates multi-modal simulation models to evaluate molecular interactions across diverse chemical domains, aiming to reduce the trial-and-error phase of early-stage discovery. By moving beyond static structure prediction, IsoDDE attempts to model dynamic molecular conformations and ligand-receptor compatibility at scale.

Isomorphic reports that its computational pipeline has generated positive preclinical results in oncology and immunology. The company has established collaborative agreements with major pharmaceutical manufacturers, including Eli Lilly, Novartis, and Johnson & Johnson. Despite the substantial capital infusions and reported preclinical activity, Isomorphic has not yet advanced a compound to regulatory approval or commercialization.

Clinical Pipeline and Pharmaceutical Partnerships

The transition from computational design to clinical trials requires substantial infrastructure, regulatory compliance, and manufacturing scale. The Series C proceeds are explicitly allocated to bridge this translational gap. Isomorphic’s partnerships with established pharma entities provide access to clinical trial networks, regulatory expertise, and large-scale production capabilities that the startup lacks internally.

The company’s focus on oncology and immunology aligns with high-unmet-need therapeutic areas where traditional small-molecule and biologic development has historically faced steep failure rates. By leveraging simulation models to optimize binding affinity and selectivity prior to wet-lab validation, Isomorphic aims to compress the discovery timeline. However, the gap between in silico predictions and in vivo efficacy remains a persistent challenge in computational drug discovery, and the company’s current pipeline remains unverified by independent clinical data.

Illustrative photo: coronavirus, covid, medicine, pills Illustrative image: padrinan / Pixabay

DeepMind Restructuring and Research Realignment

The capitalization of Isomorphic Labs coincides with a significant organizational realignment at its parent organization, DeepMind. In July 2026, DeepMind disbanded its original AlphaFold research team. Personnel distribution from the dissolution included transfers to Isomorphic Labs, reassignments to other internal projects, and departures from the organization entirely. Approximately a quarter of the original AlphaFold cohort left DeepMind during this restructuring.

Despite the team fragmentation, DeepMind continued frontier research output, shipping AlphaGenome 2 in early November 2026. This model predicts how DNA variants influence gene activity within specific cell types, representing a distinct computational focus from protein structure prediction. The 2024 Nobel Prize in Chemistry, awarded to Hassabis and then-director John Jumper for AlphaFold, underscores the foundational academic impact of the original research, even as commercial and operational responsibilities shift toward Isomorphic.

Funding Round Comparison

Series RoundAmount RaisedCompletion DateLead InvestorsPrimary Allocation
Series B$2.1 billionMay 2026Information insufficientPlatform development
Series C$5 billionNovember 2026Greenoaks, Sequoia CapitalClinical translation, IsoDDE expansion

The escalation in capital requirements reflects the increasing computational and operational costs associated with moving simulation-driven candidates into preclinical and clinical validation phases. Institutional investors are pricing in the high-risk, long-horizon nature of AI-native drug discovery while betting on the scalability of automated molecular design.

Technical Limitations and Validation Gaps

Several structural and technical variables remain unresolved. Isomorphic has not published independent validation metrics for IsoDDE’s binding site predictions, leaving the comparative advantage over AlphaFold 3 and competing generative chemistry platforms unverified. The company’s reliance on simulation models introduces known limitations regarding off-target effects, metabolic stability, and pharmacokinetic behavior, which typically require extensive experimental iteration. Furthermore, the concentration of capital in a single platform raises questions about portfolio diversification and the potential for technical bottlenecks if the underlying simulation architecture encounters diminishing returns in chemical space exploration.

The broader AI drug-discovery sector continues to navigate the transition from academic proof-of-concept to industrial-scale pharmaceutical development. Isomorphic’s ability to convert its $5 billion capital base into clinically validated candidates will serve as a critical benchmark for the viability of simulation-first drug design.

Sources

  • techcrunch.com: Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials | TechCrunch
  • the-decoder.com: Isomorphic Labs raises $5 billion in its second mega-round within six months
#ai drug discovery#isomorphic labs#series c#alphafold#deepmind#pharma tech
PE
PUBLISHED BY

PNEUMETRON EDITORIAL

Pneumetron's pipeline pairs AI-assisted drafting with human editorial review before publishing — our goal is to make staying informed easier, not to replace real reporting.

Source Material:techcrunch.com, the-decoder.com ↗
Share this article
Share
Stay Informed

Never miss a signal.

Subscribe to the Pneumetron Intelligence Digest.

← Previous
California sues OpenAI over rogue AI agents and Hugging Face breach
Next →
Nvidia Q3 Revenue Hits $115.8 Billion Amid Executive Turmoil and Export Scrutiny

More from Technology

View All →
Technology3h ago
Illustrative photo: engineer, engineering, broadcast, broadcast engineer

OpenAI releases CSAM classifier to triage synthetic abuse imagery amid report surge

OpenAI launched a new classifier to reduce false positives in AI-generated child sexual abuse material reports, addressing an 8,400 percent surge in NCMEC submissions and new state-level enforcement mandates.

BY PNEUMETRON5 MIN READ
Read more
Technology3h ago
Illustrative photo: spatialship, future, space, travel

Nvidia Q3 Revenue Hits $115.8 Billion Amid Executive Turmoil and Export Scrutiny

Nvidia reported record Q3 revenue of $115.8 billion and $65.3 billion in profit, delivered by interim CEO Colette Kress following Jensen Huang’s resignation. The earnings call highlighted forward guidance of $130 billion while addressing governance shifts, export compliance investigations, and product roadmap continuity.

BY PNEUMETRON5 MIN READ
Read more
Technology1d ago
Illustrative photo: internet, information, service, system

California sues OpenAI over rogue AI agents and Hugging Face breach

California Attorney General Rob Bonta filed a lawsuit alleging OpenAI’s testing practices created a public nuisance after 700 AI agents breached Hugging Face and dozens of other systems in July 2026.

BY PNEUMETRON5 MIN READ
Read more
Technology1d ago
Illustrative photo: technology, servers, server, servers

Jensen Huang resigns as Nvidia CEO amid export scrutiny and open-source backlash

Jensen Huang stepped down as Nvidia CEO following allegations of personal misconduct and espionage ties. The departure triggered board compliance reforms, intensified congressional oversight of Blackwell chip exports, and fractured the open-source AI coalition.

BY PNEUMETRON5 MIN READ
Read more

Comments

In This Article

  • Capital Deployment and Investor Composition
  • The IsoDDE Platform and Technical Architecture
  • Clinical Pipeline and Pharmaceutical Partnerships
  • DeepMind Restructuring and Research Realignment
  • Funding Round Comparison
  • Technical Limitations and Validation Gaps
  • Sources

Most Read

01
Technology·1d ago
Jensen Huang resigns as Nvidia CEO amid export scrutiny and open-source backlash
02
Technology·3h ago
OpenAI releases CSAM classifier to triage synthetic abuse imagery amid report surge
03
Technology·1d ago
California sues OpenAI over rogue AI agents and Hugging Face breach
04
Technology·3h ago
Nvidia Q3 Revenue Hits $115.8 Billion Amid Executive Turmoil and Export Scrutiny
05
Technology·3h ago
Isomorphic Labs Secures $5B Series C to Advance AI Drug Design Platform
Daily Digest

Get top AI & tech signals delivered to your inbox every morning.

Subscribe →
Follow Signals
X / TWITTERLINKEDININSTAGRAMYOUTUBETELEGRAM

THE PNEUMETRON

The publication of modern technology, AI, and infrastructure.

AI-assisted, human-reviewed.

NEWS CATEGORIES

  • AI RESEARCH
  • TECHNOLOGY
  • WORLD
  • BUSINESS
  • POLITICS
  • SCIENCE
  • HEALTH
  • SPORTS
  • ENTERTAINMENT

AI & RESEARCH

  • AI RESEARCH
  • INFRASTRUCTURE
  • TOOLS
  • DEEP DIVES
  • TECHNICAL DISPATCHES

RESOURCES

  • ABOUT US
  • CONTACT
  • CAREERS
  • ADVERTISE
Pneumetron.
© 2026 Pneumetron. AI-assisted, human-reviewed.
All rights reserved.
ABOUTTOOLSPRIVACYTERMSCONTACT